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Background: TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a
potential treatment for patients with mild-to-moderate Alzheimer’s disease (AD). A previous report describes
decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multiple imputation), relative to
placebo, following a 5 mg/day dose of TTP488. Acute, reversible cognitive worsening was seen with a 20 mg/day
dose. The present study further evaluates the efficacy of TTP488 by subgroup analyses based on disease severity
and concentration effect analysis.
Methods: 399 patients were randomized to one of two oral TTP488 doses (60 mg for 6 days followed by 20 mg/
day; 15 mg for 6 days followed by 5 mg/day) or placebo for 18 months. Pre-specified primary analysis, using an ITT
population, was on the ADAS-cog11. Secondary analyses included as a key secondary variable the Clinical Dementia
Rating-Sum of Boxes (CDR-SB), and another secondary variable of the ADCS-ADL.
Results: On-treatment analysis demonstrated numerical differences favoring 5 mg/day over placebo, with nominal
significance at Month 18 (delta = 2.7, p = 0.03). Patients with mild AD, whether defined by MMSE or ADAS-cog,
demonstrated significant differences favoring 5 mg/day on ADAS-cog and trends on CDR-sb and ADCS-ADL at
Month 18. TTP488 plasma concentrations of 7.6-16.8 ng/mL were associated with a decreased decline in ADAS-cog
over time compared to placebo. Worsening on the ADAS-cog relative to placebo was evident at 46.8-167.0 ng/mL.
Conclusions: Results of these analyses support further investigation of 5 mg/day in future Phase 3 trials in patients
with mild AD.Background
Alzheimer’s Disease (AD) is a neurodegenerative disorder
with aspects of inflammatory, metabolic and vascular
pathology [1,2]. An overproduction of amyloid beta (Aβ)
has been implicated as the leading mechanistic factor in
AD pathology. Aβ is known to bind to The Receptor for
Advanced Glycation Endproducts (RAGE) an immuno-
globulin supergene family member expressed on multiple
cell types in the brain and the periphery [3,4]. RAGE is
found on the cells of the neurovascular compartment:
endothelial cells and microglia prominently express RAGE
whose expression is upregulated in AD [5,6]. RAGE li-
gands include Aβ, S100b, HMGB1 and Advanced Glyca-
tion Endproducts. RAGE-ligand interactions lead to
sustained inflammatory states that play a role in chronic* Correspondence: aburstein@ttpharma.com
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reproduction in any medium, provided the ordiseases such as diabetes, inflammation, and AD [7,8]. In
AD, RAGE has been proposed to contribute to AD path-
ology by: promoting vascular leakage, promoting influx of
peripheral Aβ into brain; mediating Aβ-induced oxidative
stress and Aβ mediated neuronal death [9-12].
The pleiotropic role of RAGE has been demonstrated in
AD pathology has been described using rodent models.
Mice expressing the human APP transgene in neurons
develop significant biochemical and behavioral changes
reminiscent of human AD. Double transgenic mouse over-
expressing WT RAGE in the APP transgene background
exhibit accelerated behavioral changes whereas double
transgenic animals expressing a dominant negative mutant
of RAGE are protected [13]. This data suggests that RAGE
plays a role in augmenting the chronic inflammatory state
caused by overproduction of Aβ.
RAGE is thought to be involved in the transport of Aβ
from peripheral to CNS compartments [14]. In vivo, Aβl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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RAGE null mice [12]. Similarly, Aβ uptake in brain can
be inhibited using either the secreted, soluble form of
RAGE (called sRAGE) or an anti-RAGE antibody [12].
In addition, plaque formation in a mouse model of cere-
bral amyloidosis was inhibited using sRAGE [15,16].
These data suggest that RAGE is intimately involved in
the pathogenesis of AD, and that sustained Aβ inter-
action with RAGE on blood brain barrier (BBB) and/or
neuronal cells is an important element of amyloid plaque
formation and chronic neuronal dysfunction.
TransTech Pharma, Inc. discovered TTP488, an orally
active, centrally acting antagonist of RAGE-RAGE ligand
interaction. Chronic oral dosing of TTP488 in AD trans-
genic mice led to a reduction of amyloid load in the
brain, improved performance on behavioral testing and
normalization of electrophysiological recordings from
hippocampal slices [17].
The results of a phase 2 study examining the safety, tol-
erability and efficacy of TTP488 in mild to moderate AD
have been reported elsewhere [18]. Briefly, 399 patients
were randomly assigned to one of two dose levels of
TTP488 (60 mg loading dose for 6 days followed by
20 mg/day; 15 mg loading dose for 6 days followed by
5 mg/day) or placebo administered orally for 18 months.
The pre-specified primary analysis, using a modified
intent-to-treat population, was on the Alzheimer’s Disease
Assessment Scale-Cognitive (ADAS-cog11). Based on a
pre-specified interim analysis when 50% of subjects had
completed the 6 month visit, the 20 mg/day dose was dis-
continued due to an increased incidence of confusion, falls
and greater ADAS-cog decline than placebo. No safety
concerns were noted for the 5 mg/day group. Approxi-
mately 12 months after all subjects were randomized a
second pre-specified interim analysis on 18-month com-
pleters compared the 5 mg/day dose and placebo groups
for futility and safety. While safety data raised no con-
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Figure 1 Estimated mean change from baseline over time on Alzheim
Increasing values represent worsening. Error bars represent one standard e
difference at 18 months = 3.1, p < 0.008; (B) ADAS-cog, on treatment obserpower to observe a significant difference between low dose
and placebo at 18 months) was met and treatment was
discontinued. Final analysis showed a decreased decline
on the ADAS-cog in the 5 mg/day group at month 18
(treatment-placebo difference = 3.1, p = 0.008, ANCOVA
with multiple imputation) (Figure 1, panel A). The differ-
ence remained significant using other planned statistical
models that cope with missing data differently (ANCOVA
on observed cases (p = 0.02), ANCOVA with LOCF (p =
0.03), mixed-models repeated measures (p = 0.04), and
GEE (p = 0.03)). The authors concluded that this post-
futility analysis suggested benefit for 5 mg/day; however,
definitive conclusions about the effects could not be made
due to operational issues (dropouts and discontinuations
from treatment) subsequent to the interim analysis.
This manuscript describes analyses of the effect of
TTP488 5 mg/day, versus placebo, on the Alzheimer’s
Disease Assessment Scale-Cognitive (ADAS-cog) [19] after
18 months of treatment, in patients on stable background
therapy with acetylcholinesterase inhibitors and/or meman-
tine, based on an “on-treatment” definition of the study
population. Additionally, analysis of the ADAS-cog, Clinical
Dementia Rating Sum of Boxes (CDR-sb) [20] and the
Alzheimer’s Disease Cooperative Study – Activities of Daily
Living scale (ADCS-ADL) [21] for mild sub-population and
characterization of the pharmacokinetic/pharmacodynamic
relationship of TTP488 to ADAS-cog are described.
Methods
This Phase 2, multicenter, randomized, double-blind,
placebo-controlled, parallel, three-arm, multiple dose
study was conducted at 40 study sites in the United States
between January 2007 and December 2010 (ClinicalTrials.
gov identifier NCT00566397.) The study was approved by
each study site’s Local Institutional Review Board (see
Additional file 1). Each patient provided written informed
consent. If patients had impaired decisional capacity, care-
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er’s Disease Assessment Scale-Cognitive subscale (ADAS-cog 11).
rror. (A) ADAS-cog Observed cases all data. Treatment-placebo
ved cases. Treatment-placebo difference at 18 months = 2.7, p = 0.03.
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Eligible patients were aged ≥ 50; met the criteria for a
diagnosis of probable AD [22]; had a MMSE [23] score
between 14 and 26, had a modified Hachinski (Rosen)
score ≤4, were receiving treatment with a stable dose of
an acetylcholinesterase inhibitor and/or memantine for ≥
4 months prior to randomization. Patients were ex-
cluded for clinically significant neurologic, psychiatric or
other diseases contributing to his/her dementia, MRI
and/or CT evidence of stroke or significant cerebrovas-
cular disease, uncontrolled hypertension, unstable car-
diac or pulmonary disease, diabetes (or hemoglobin A1c
at screening > 6%).
Study design and treatment
Enrollment targeted 399 patients (133 per group), ran-
domized (1:1:1) to placebo, or TTP488 20 mg daily (after a
loading dose of 60 mg daily for 6 days), or 5 mg daily (after
a loading dose of 15 mg daily for 6 days), for 18 months.
An independent Data and Safety Monitoring Board
(DSMB) monitored the safety of subjects in the trial.
Study visits occurred at screening, baseline, then at four
weeks, 3, 6, 9, 12, 15, 18 months, with a safety follow-up
visit at 21 months. Visits included clinical and safety eval-
uations, blood draw for plasma biomarker and pharmaco-
kinetic analysis, and pill counts to assess compliance.
Brain MRIs were obtained at baseline, 12 and 18 months.
Lumbar punctures for CSF biomarkers were performed at
baseline and 12 months on a subgroup of subjects.
Outcome measure
The primary efficacy measure was the ADAS-cog [21].
The ADAS-cog/12-item (scored 0–80) scale was admin-
istered before the first dose, and at 3, 6, 9, 12, 15 and 18
months with the pre-specified analyses being on the
ADAS-cog/11-item scale (Scored 0–70). The key sec-
ondary clinical measure was the CDR-sb [22]. The
ADCS-ADL was included as a secondary measure [23].
Both CDR-sb and ADCS-ADL were administered prior
to dosing and at months 6, 12 and 18.
Pharmacokinetic assessments
Blood samples for TTP488 PK analysis were collected
prior to dosing at Week 1, at Months 1, 3, 6, 9, 12, 15,
18, and 21 and at Early Termination.
Statistical analysis
Populations
The full analysis set (FAS) consisted of all subjects who
received at least 1 dose of study medication, and had a
baseline (if applicable for the endpoint being analyzed)
and post-baseline observation for the measurement of
interest. The results of this analysis have been presented
previously [18]. The on-treatment analysis set wasdefined as all available on treatment data, where “on
treatment” was defined as date of last dose plus 45 days
(this definition was used because the drug has a long ½
life of 10–20 days).
Primary analysis
The primary analysis planned in the study protocol com-
pared differences in mean treatment effect using 5 statis-
tical methodologies that cope with missing data in different
ways, with multiple-imputation methods demarked as pri-
mary and others as supportive (supportive methods in-
cluded endpoint analysis, observed cases, generalized
estimating equations (GEE), and mixed-models repeated
measures on the longitudinal data). Point estimates, stand-
ard errors, confidence intervals, and p-values were com-
puted using the statistical models as planned. For all
analyses alpha = 0.05, as the supportive analyses were
planned to ensure robustness against missing data.
Baseline measures of the variable of analysis are recom-
mended covariables for statistical modeling [24]. Subgroup
analysis for covariables of baseline severity of AD can be
based on MMSE or ADAS-cog, the latter of which is the
variable of analysis. Use of the baseline ADAS-cog can re-
duce heterogeneity, thereby increasing the sensitivity of
detecting delineation between treatments.
Pharmacokinetic/pharmacodynamic analyses
Blood samples (5 mL) for TTP488 plasma concentra-
tions were collected in dipotassium (K2) EDTA tubes
prior to dosing at Week 1, months 1, 3, 6, 9, 12, 15, 18,
21 and at Early Termination. Samples were centrifuged
at approximately 1700 g for about 10 minutes at 4°C
with plasma stored in polypropylene tubes at approxi-
mately -20°C within 1 hour of collection. Plasma sam-
ples were analyzed for TTP488 concentrations using a
validated HPLC-MS/MS method.
Exploratory analyses relating TTP488 plasma concen-
tration (including the 20 mg/day and 5 mg/day dose
groups) to ADAS-cog values, and changes over time, uti-
lized deriving a subject-level value by two methods: (1)
deriving the subject level value by the maximum of the
trough concentration values for that subject over the 18-
month period, and (2) deriving the subject level value by
taking the median concentration value for that individ-
ual. Analyses were done at the subject level.
Subjects were classified into concentration groups ac-
cording to quintile cut-points in the distribution of con-
centration values ignoring administered dose.
Analysis of mild vs. moderate subgroups
Protocol-planned analyses included subgroup analysis
based on baseline severity of AD. ADAS-cog and CDR-sb
changes from baseline were analyzed (ANCOVA adjusted
for baseline main effects) by baseline disease severity using
Table 1 Patient demographic and baseline clinical






(n = 135) (n = 131) (n = 133)
Age (years) 73.0 ± 9.0 73.6 ± 8.8 72.2 ± 9.6
Sex (% women) 61 53 57
Race
White 128 120 125
Education (years) 15.0 ± 3.0 14.8 ± 2.8 15.3 ± 2.8
MMSE 19.9 ± 3.6 20.8 ± 3.5 20.5 ± 3.4
Mild (MMSE ≥20), n(%) 71 (53%) 84 (64%) 81 (61%)
Moderate (MMSE < 20), n(%) 64 (47%) 47 (36%) 51 (39%)
ADAS-cog 24.9 ± 9.7 24.4 ± 9.8 24.1 ± 9.6
CDR-sb 5.7 ± 2.9 5.6 ± 2.7 6.0 ± 2.8
ADCS-ADL 61.3 ± 12.9 61.4 ± 12.3 59.9 ± 12.8
NPI 7.9 ± 10.5 7.7 ± 10.3 8.6 ± 10.4
APOE e4+status, n (%) 62 65 74
E2/E3 3 (2.3%) 5 (4.2%) 1 (0.9%)
E2/E4 7 (5.4%) 2 (1.7%) 2 (1.7%)
E3/E3 46 (35.7%) 36 (30.5%) 30 (25.6%)
E3/E4 47 (36.4%) 53 (44.9%) 59 (50.4%)
E4/E4 26 (20.2%) 20 (16.9%) 25 (21.4%)
Unknown/Missing 6 15 16
AchEI use, n(%) 134 (99%) 129 (98%) 132 (100%)
Memantine use, n (%) 92 (68%) 87 (66%) 96 (73%)
Unless otherwise indicated, data reported as mean ± SD.
MMSE =Mini-Mental State Examination, ADAS-cog = Alzheimer’s Disease
Assessment Scale cognitive. CDR-sb = Clinical Dementia Rating sum of boxes,
ADCS-ADL = Alzheimer’s Disease Cooperative Study Activities of Daily Living
Scale, NPI = Neuropsychiatric Inventory, APOE e4 = Apolipoprotein E e4 allele,
AchEI = acetylcholinesterase inhibitor.
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ADAS-cog, CDR-sb and ADCS-ADL were additionally
evaluated (2-sample t-test) using an ADAS-cog based defin-
ition of mild AD (ADAS-cog ≤ 19). An ADAS-cog value of
19 was selected based on conversion of a traditional cut-off
of an MMSE value of 20, used in the analyses reported
above, to a corresponding ADAS-cog value using the previ-
ously described linear relationship between ADAS-cog and
MMSE (ADAS-cog = 56.4-1.86*MMSE) [25].Table 2 Changes from baseline in ADAS-cog for on-treatment
3 months 6 months 9 month
5 mg/day 1.43 ± 0.50 2.52 ±0.56 3.02 ± 0.6
(n = 126) (n = 118) (n = 106
Placebo 1.58 ± 0.44 3.16 ± 0.54 3.99 ± 0.6
(n = 127) (n = 114) (n = 109
Data presented as mean ± standard error.Sample size
With approximately 133 subjects per group, the primary
study had 80% power to detect a 3 point difference in
change from baseline to 18 months in ADAS-cog scores
between a TTP488 dose group and placebo, allowing for
25% missing data and two interim analyses. ADAS-cog
18- month changes from baseline were assumed to have
a standard deviation of 6.5 points for all treatment




Patient disposition has been described previously [18].
Briefly, 701 subjects were screened for eligibility, 302
were excluded and 399 were randomized. Subjects were
well matched for demographic characteristics with no
significant differences between groups (Table 1).
On-treatment analysis
Statistical analysis on ADAS-cog was performed using
all available on-treatment data. Beginning with Month
3, there were 127 subjects in the placebo group and 126
subjects in the 5 mg/day dose group with baseline and
on-treatment data. Mean changes and median changes
in ADAS-cog are consistent in showing numerical
active-placebo differences favoring the 5 mg/day dose
group over time. (Table 2, Figure 1, panel B) At all time
points, the numerical difference favors the 5 mg/day
dose group over placebo, with nominal significance at
Month 18 (Δ=2.7, p = 0.03).
Exploratory analysis by disease severity
Analysis was performed on the FAS (ITT) comparing
ADAS-cog and CDR-sb in patients with mild AD
(MMSE ≥20) and moderate AD (MMSE < 20)). For
ADAS-cog, a 3.3 point (p = 0.024) and 2.7 point (p = 0.4)
difference between 5 mg/day and placebo was seen at
Month 18 in the mild group and moderate group, respect-
ively. For CDR-sb , a 0.72 point (p = 0.053) and 0.74 point
(p = 0.5) difference between 5 mg/day and placebo was
seen at Month 18 in the mild group and moderate
group, respectively. These findings were confirmed in
post-hoc subgroup analyses defining mild patients aspopulation
s 12 months 15 months 18 months
2 5.14 ± 0.75 7.18 ± 0.81 8.96 ± 1.07
) (n = 95) (n = 83) (n = 63)
8 6.26 ± 0.69 8.74 ± 0.91 11.63 ± 1.15
) (n = 101) (n = 86) (n = 59)
p = 0.03
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ment group, observed cases at 18 months). These ana-
lyses reveal a delta at 18 months, favoring 5 mg/day
over placebo, on ADAS-cog of 5.9 points (p < 0.01) and
trends on CDR-sb (delta = 1, p = 0.08) and ADCS-ADL
(delta = 4.92, p = 0.07) (Figure 2). The beneficial effect
of 5 mg/day in patients with moderate AD (ADAS-A
B
C
Figure 2 Estimated mean change from baseline over time on ADAS-c
disease defined as either MMSE ≥20 (Panels A, B and C) or ADAS-cog
error. (A) ADAS-cog treatment-placebo difference at 18 months = 3.3, p = 0
18 months = 0.72, p = 0.053, Baseline MMSE ≥ 20; (C) ADCS-ADL treatment
(D) ADAS-cog treatment-placebo difference at 18 months = 5.9, p < 0.008, B
months = 1, p = 0.08, Baseline ADAS-cog≤ 19; (F) ADCS-ADL treatment-placog >19) was less pronounced with a delta (5 mg/day vs.
placebo) at 18 months of 1.45 for ADAS-cog, 0.74 for
CDR-sb, and 0.57 for ADCS-ADL.
TTP488 Plasma concentration driven analysis
As expected, higher plasma TTP488 trough concentra-
tions (mean, median of trough concentrations over theD
og 11, CDR-sb and ADCS-ADL for patients with mild Alzheimer’s
≤19 (Panels D, E, F) at baseline. Error bars represent one standard
.024, Baseline MMSE ≥ 20; (B) CDR-sb treatment-placebo difference at
– placebo difference at 18 months = 2.2, p = 0. 3, Baseline MMSE ≥ 20
aseline ADAS-cog≤ 19; (E) CDR-sb treatment-placebo difference at 18
cebo difference at 18 months = 4.92, p = 0.07, Baseline ADAS-cog≤ 19.
Table 3 TTP488 median and mean trough concentrations associated with the 5 mg/day and 20 mg/day dose groups





interval of the mean
(ng/mL) (ng/mL)
Median of subjects’ trough values 5 mg/day (n = 131) 13.02 12.25 [11.74, 14.31]
20 mg/day (n = 134) 68.57 64.58 [63.46, 73.69]
Mean of subjects’ trough values 5 mg/day (n = 131) 16.22 14.90 [14.59, 17.85]
20 mg/day (n = 134) 83.75 75.05 [77.40, 90.10]
Mean and median concentration across the measured timepoints was determined for each subject. Descriptive statistics (mean, median) subsequently provided
for each measure.
aMean TTP488 concentration across the 18 months, or available time points, for each individual subject. Each subject contributes a single value.
bMedian TTP488 concentration across the 18 months, or available time points, for each individual subject. Each subject contributes a single value.
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duration) were observed for 20 mg/day, and lower con-
centrations observed for 5 mg/day (Table 3, Figure 3).
Within certain concentration ranges, delineation from
placebo in changes in ADAS-cog was more pronounced
than in other ranges (Table 4). Subjects with concentra-
tions in the lowest 20% (0.1-10.2 ng/mL) and second
lowest 20% (10.3-16.8 ng/mL) showed benefit over pla-
cebo at 18 months. The effect in the 0.1-10.2 ng/mL
group was primarily driven by those subjects with con-
centrations greater than 7.6 ng/mL. Subjects in the middle
20% group (17.0-46.3 ng/mL) showed similar effects as
placebo. Subjects in the top two groups (46.8-71.7 ng/mL
and 74.0-167.0 ng/mL) showed a numerical worsening in
ADAS-cog relative to placebo through 12 months after
which time the number of subjects in these quintiles is too
few to allow for meaningful interpretations.
Discussion
This Phase 2 trial explored the safety and efficacy of 2 doses
levels of TTP488, compared to placebo, in patients withFigure 3 TTP488 plasma concentration over time. On-treatment data w
within 45 days of last administered dose. Data presented as mean values w
presented through Month 15 after which there were too few observationsmild-to-moderate AD. Post-futility, protocol-specified
analyses of changes in ADAS-cog showed a favorable ef-
fect in the 5 mg/day dose group compared to placebo at
month 18. Sensitivity analyses using methodologies that
cope with missing data differently indicated that conclu-
sions were invariant to statistical model or methodology,
thereby supporting the robustness of the result. Post-hoc
analyses of subjects “on treatment” also demonstrated sig-
nificant treatment effects for the 5 mg/day dose group.
Effects on the ADAS and CDR-SB were slightly greater
and similar in magnitude, respectively, in mild versus mo-
derate subjects defining each subgroup based on MMSE.
Given the MMSE is a brief screening test, analyses based
on an ADAS-cog based definition of mild AD (consistent
with recommended statistical methodologies for accom-
modating baseline measures of the variable of analysis as a
covariable) provide additional confirmation of the effect of
TTP488 in patients with mild AD. The inability to demon-
strate a significant effect on the ADAS-cog and CDR-sb,
despite clinically meaningful numerical effect sizes, in
moderate subjects is presumably due the smaller grouphere on-treatment is defined as plasma concentrations measured
ith 95% confidence boundary. For the 20 mg/day group data
.
Table 4 Changes from baseline in ADAS-cog for each quintile TTP488 concentration range over 18 months
of treatment
Month Placebo 0.1-10.2 ng/mL 10.3-16.8 ng/mL 17.0-46.3 ng/mL 46.8-71.7 ng/mL 75-167 ng/mL
3 1.59 (0.43) 0.83 (0.75) 1.35 (0.74) 2.51 (0.77) 4.42 (0.84) 7.4 (0.94)
n = 129 n = 50 n = 51 n = 52 n = 47 n = 48
6 3.14 (0.54) 2.24 (0.85) 2.3 (0.87) 4 (0.88) 4.7 (0.82) 9.1 (1)
n = 115 n = 48 n = 49 n = 48 n = 37 n = 46
9 4.3 (0.7) 1.9 (0.9) 3 (0.93) 4.3(1.1) 5.1 (1.45) 8.4 (1.3)
n = 112 n = 39 n = 46 n = 42 n = 27 n = 40
12 6.4 (0.68) 3 (0.76) 5.6 (1.22) 6.7 (1.3) 7.4 (1.67) 9.3 (1.3)
n = 105 n = 32 n = 42 n = 37 n = 22 n = 31
15 9.9 (0.9) 6.8 (0.98) 6.9 (1.42) 8.1 (0.4) 9.3 (1.97) 10.1 (1.9)
n = 89 n = 30 n = 37 n = 30 n = 21 n = 24
18 11.9 (1.1) 8.7 (1.36) 8.1 (1.71) 10.1 (2) 10.1 (2.47) 11.3(1.8)
n = 64 n = 25 n = 26 n = 25 n = 15 n = 19
Data are reported as mean (sd), n.
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TTP488 may impart beneficial effects in both mild and
moderate subjects, enrichment of a study population for
mild subjects may allow for not only a greater magnitude
of effect but early demonstration of clinical effects.
The results of analyses of ADAS-cog, based on plasma
concentrations suggest 5 mg/day, associated with plasma
concentrations of 7.6-16.8 ng/mL, as a dose that would be
associated with beneficial effects on cognition relative to
placebo. While concentrations above 46.8 ng/mL were as-
sociated with reversible worsening of cognition in TTP488
treated subjects, the ability to safely dose subjects in the
concentration range of 17.0-46.3 ng/mL provides an ad-
equate safety margin for the 5 mg/day dose thereby allow-
ing for accommodation of increased intersubject variability
that may be seen in an expanded Phase 3 population.
Conclusions
This Phase 2 trial demonstrated a 3.1 point difference in
ADAS-cog at 18 months for the 5 mg/day dose relative
to placebo in patients with mild-to-moderate AD; an ef-
fect supported by “on-treatment” analyses of the data.
Secondary analyses evaluating the effect in mild patients
demonstrated a significant effect on ADAS-cog and
trend on CDR-sb and ADCS-ADL at 18 months. This
finding supports the enrichment of future TTP488 trials
with mild subjects, to allow for demonstration of effects
with a dose of 5 mg/day plus standard of care.
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